Dedicated HF trials powered for lipid-centric primary endpoints - such as ApoB, small-dense LDL, LDL particle number, HDL functionality, and lipidomic profiling - are needed to clarify the clinical significance of these adaptations. This evidence concerns the gene APOB and hydrops fetalis.